90 A new class of immune-based therapies is showing promise in treating one of the most difficult stages of prostate cancer, with researchers hopeful that T-cell engagers could transform the outlook for men with metastatic castration-resistant prostate cancer. The findings were published in the journal European Urology. Traditional immunotherapies have largely failed to make a significant impact on advanced prostate cancer, due in part to what researchers call a “cold” tumour environment, where the immune system struggles to recognise and attack cancer cells. However, T-cell engagers – engineered molecules that redirect the immune system to attack cancer – are being developed to bypass these challenges. These novel agents work by linking a patient’s T cells with specific proteins found on prostate cancer cells. This connection triggers the immune system to destroy cancer cells more efficiently, regardless of the tumour’s ability to hide from immune surveillance. Several of these agents have already entered early clinical trials, showing encouraging results, though not without risks. One candidate, acapatamab, demonstrated a measurable reduction in prostate-specific antigen levels in nearly a third of patients treated. Yet the drug was eventually withdrawn from development because of a high incidence of cytokine release syndrome, a potentially dangerous inflammatory reaction. Similarly, xaluritamig, targeting a different prostate cancer protein known as STEAP-1, produced stronger results, with almost half of patients achieving significant responses and fewer experiencing severe side effects. More recent studies are also focusing on trispecific engagers, which add a third binding domain to extend the treatment’s lifespan in the body. Trials of HPN424 and HPN328, two of the most advanced trispecific candidates, suggest these agents could offer better tumour targeting while maintaining a more manageable safety profile. Despite these advances, obstacles remain. Many of the trials report the development of antidrug antibodies, which can interfere with treatment effectiveness over time. The safety concerns associated with T-cell activation, particularly excessive immune responses, have also limited the use of these agents outside of trial settings. Researchers believe the future of T-cell engagers may lie in combination therapy. Trials are now under way testing these agents alongside other cancer drugs such as androgen receptor inhibitors and checkpoint blockers. Early data suggest this approach could improve outcomes without compounding toxic effects. Another strategy being explored involves using biomarkers to identify which patients are most likely to benefit. For instance, higher levels of a target protein like PSMA in scans have been linked to stronger responses to certain T-cell engagers. Administering these therapies earlier in the course of the disease, when patients are generally healthier, may also increase their effectiveness. As trials progress, oncologists remain cautiously optimistic. The next phase will focus on refining treatment protocols, determining safe combinations, and understanding which patients are most likely to benefit. While it is still early days, T-cell engagers could represent the most significant advance in prostate cancer immunotherapy in years.